GOG-3116
A Prospective Low-Interventional Phase I Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer
This is a single-arm, prospective, low-interventional study of tisotumab vedotin in adult participants in the US with r/mCC who have received prior systemic therapy for their recurrent or metastatic disease. Participants will receive tisotumab vedotin 2 mg/kg once every 3 weeks (Q3W) by intravenous (IV) infusion and managed according to local standard practice.